Royalty Report: Delivery, Drugs, Medical – Collection: 233493


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Delivery
  • Drugs
  • Medical
  • Device
  • Therapeutic
  • Dialysis
  • Diabetes Treatment

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233493

License Grant
The Licensee of Bermuda wishes the Licensor of Bermuda to develop the System as a method of drug delivery incorporating the compound for the Field.

The Licensor of Bermuda grants to the Licensee of Bermuda an exclusive license to the Licensors Background Technology and Licensors Improvements to package, import, use, offer for sale and sell and otherwise distribute the Product for the Field in the Territory.

Licensor also grants a non-exclusive license in the Territory to use the Licensors Trademark solely for the purposes of exercising its rights and performing its obligations under this Agreement.

License Property
The patents and technology are for Medipad, and, an Improved Method of Packaging a Drug Delivery Kit .

The Compound shall mean any formulations of Desferoxamine and any of its analogues, isomers or derivatives.

The System shall mean the ambulatory subcutaneous infusion drug delivery system for direct attachment to the body of a patient having a flexible diaphragm drug reservoir, which is capable of delivering factory pre-programmed continuous amounts of drug upon activation as disclosed and described in the Licensors patents.

Deferoxamine (DFOA) is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.

Field of Use
The field shall mean the treatment of any iron overloading disorder by subcutaneously delivering the Compound using the System.

IPSCIO Record ID: 164315

License Grant
The Irish Licensor grants the Licensee of Bermuda an exclusive license to the Licensors Technology for all research, development, and commercial purposes solely in the Field, but not beyond the Field.

Licensor grants the Licensee a non-exclusive license, or, if applicable, sublicense, to use the Licensors Trademarks, upon or in relation to the promotion, marketing, advertising, sale or offering for sale of the Licensors Royalty Products.

License Property
The trademark license includes Medipad(TM) and Elan(R).

The Licensors Medipad System Patent Portfolio includes, among others, patents and applications for Method and Device for Entrapping a Volume of Gas in a Liquid Drug Container,  Improved Method of Packaging a Drug Delivery Kit,  Cartridge-Based Drug Delivery Device and Medicament Delivery Device.

Medipad/TM/ is a lightweight, disposable drug delivery system, which combines the simplicity of a patch with the extensive delivery capabilities of an infusion pump.

Field of Use
The field of use is for the research, development, and commercialization of Iron chelating agents and the Substitute Compounds.

IPSCIO Record ID: 263340

License Grant
Licensor hereby grants and Licensee hereby accepts an exclusive, sublicenseable, royalty-bearing license for use of Licensor Technology to make, have made, use, offer for sale, export, import, and sell licensed products, in the licensed field of use in the licensed territory during the term.
License Property
IV TRIFERIC® is certain intravenous (“IV”) delivered products incorporating SFP (soluble ferric pyrophosphate) including those for replacement/maintenance of iron, management of iron disorders,  preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia in any and all indications where SFP delivered by IV, may be useful.

Licensor owns certain patent rights, trade secrets, know how, and other proprietary information and technology related to the use of soluble ferric pyrophosphate (“SFP”) including for use in management of iron disorders including preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia.

Licensed Products means all compositions of matter, formulations, articles of manufacture, materials, and products using, including, comprising or incorporating SFP or any specific species thereof, including generics, in the licensed field of use that incorporate the Licensor Technology.

Licensor Patent Rights means
6,779,468 – United States – Issued 08/24/2004 – Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
61/759531 – United States – Application
14/765111 – United States – Application
14/765111 – United States – Application

Field of Use
Licensed Field of Use is limited to only IV formulations of SFP and IV formulations of specific species of SFP, and indications treated by such IV formulations of SFP and its specific species. For clarity, the Licensed Field of Use expressly excludes non-IV formulations for instance delivery of SFP via a dialysate solution which is the subject of the 2002 Agreement as amended. SFP formulations for other modes of delivery, e.g., transdermal, shall require additional licenses, which the PARTIES shall negotiate in good faith should the occasion arise; and Licensee shall have no implied or actual license or other right to exploit or commercialize any non-IV formulations for delivery of SFP through any such other modes of delivery which are based in any manner upon Licensor Technology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.